大脑小血管疾病与中间叶中蛋白质病变之间的关系
Valentina Perosa1, Jan Oltmer2, Francesco Bax3,4
1J. Philip Kistler Stroke Research Center, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Cambridge Str. 175, Suite 300, Boston, MA, 02114, USA. VPEROSA@mgh.harvard.edu.
Acta neuropathologica communications
|July 16, 2025
概括
大脑小血管疾病 (CSVD) 和阿尔茨海默氏症 (AD) 蛋白质病在中间叶共存. 大脑粉样血管病变 (CAA) 与AD蛋白质病变有关,而动脉样硬化可能会损害大脑清除.
科学领域:
- 神经病理学神经病理学
- 神经退行性疾病 神经退行性疾病
- 脑血管疾病 脑血管疾病
背景情况:
- 中间叶 (MTL) 对认知和阿尔茨海默氏症 (AD) 病原发生至关重要.
- 大脑小血管疾病 (CSVD) 独立影响认知,并可能与AD相互作用.
- 在MTL中,CSVD亚型和AD相关蛋白病变之间的相互作用尚未得到充分理解.
研究的目的:
- 在MTL中量化评估CSVD的严重程度及其与AD蛋白病变 (tau-tangles,粉样β-斑块,pTDP-43) 的关联.
- 为了研究CSVD和扩大周血管空间 (PVS) 之间的关系,作为受损清除的标志物.
主要方法:
- 从152个尸体解剖病例中对数字化MTL组织学进行人工智能和人工分析.
- 脑粉样血管病变 (CAA) 和动脉样硬化症的量化.
- 评估陶结,粉样蛋白β斑块和pTDP-43负担.
- 线性混合效应模型分析CSVD,蛋白质病变和PVS扩大之间的关联.
主要成果:
- CAA负担与布拉克阶段相关,并且与粉样β斑块和团有关,独立于布拉克阶段.
- 动脉样硬化症的严重程度与对细胞蛋白质病变没有直接关联.
- 动脉样硬化及其与CAA的相互作用与PVS扩大有关,这表明周血管清除受损.
结论:
- 大脑粉样血管病变 (CAA),一种CSVD形式,直接涉及到MTL蛋白质病变的病理生理学.
- 动脉样硬化,另一种CSVD形式,可能会导致MTL中周血管清除功能障碍.
- 这些发现凸显了CSVD亚型在AD病原和脑清除机制中的独特作用.
相关概念视频
Amyloid Fibrils
9.9K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.9K
Alzheimer's Disease: Overview
673
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
673


